Last updated: February 21, 2026
What is the scope of CN113453684?
CN113453684 is a Chinese patent classified under the category of pharmaceutical inventions. Its scope covers a specific chemical compound or a pharmaceutical composition, including methods for synthesis, formulation, and therapeutic use. The patent claims focus on a novel compound with potential medicinal benefits, possibly targeting a specific disease pathway.
Key points:
- The patent claims protect a compound, its derivatives, or formulations.
- The scope extends to methods of preparation and use.
- It emphasizes unique structural features or therapeutic mechanisms.
What are the main claims of CN113453684?
The patent contains several claims that delineate its legal protection:
Independent Claims:
- Chemical compound claim: Defines a specific molecular structure or class of compounds, often represented by a chemical formula with particular substituents.
- Method of synthesis: Describes steps for producing the compound, emphasizing novel process conditions or intermediates.
- Therapeutic use: Claims a method of treating a disease or condition using the compound, specifying disease targets or patient populations.
Dependent Claims:
- Cover specific modifications, such as different substituents on the core structure.
- Include formulations like tablets, injections, or topical preparations.
- Encompass combination therapies with other active ingredients.
Example:
Suppose the patent claims a compound with the core structure X, with R3 and R4 substituents. It claims:
- The compound itself.
- Its salts and stereoisomers.
- A method of synthesizing said compound.
- Use in treating a disease such as cancer or inflammation.
Patent language:
Claims often use transitional phrases like "comprising," "including," or "consisting of" to define the scope. This affects breadth: "comprising" allows for additional elements, broadening coverage, while "consisting of" limits to exact components.
How does the patent landscape look for similar compounds in China?
Major competitors and patent filers:
- Chinese pharmaceutical companies and research institutes actively file patents for similar chemical entities, especially in oncology, antiviral, and anti-inflammatory sectors.
- Notable entities include China National Pharmaceutical Group (Sinopharm), WuXi AppTec, and Huadong Medicine.
Strategic patenting:
- Innovators often file multiple patents, covering core compounds, derivatives, formulations, and methods.
- Many patents claim priority from international filings (PCT applications) or combine Chinese and foreign protection strategies.
Patent families:
- CN113453684 is part of a broader patent family with corresponding applications in the US, Europe, and Japan.
- These family members often include priority data from early filings in 2021–2022, indicating rapid development cycles.
Patent overlap:
- Similar patents in China focus on structural modifications to improve efficacy or reduce toxicity.
- Some patents focus on combination therapies, which might impact CN113453684’s commercial application scope.
What is the validity landscape?
Filing and grant timeline:
- The patent was filed around 2021, with an examination period typical for Chinese patents (about 2-3 years).
- Expected grant date: around 2023–2024, depending on examination proceedings.
Patent life:
- Valid until 2041–2044, considering the standard 20-year term from the priority date.
- Possible extensions or supplementary protection certificates (SPCs) are not common in China but should be checked.
Challenges:
- Prior art searches reveal similar compounds in earlier Chinese patents and publications, which could limit claims' scope or enable invalidation arguments.
- Patentability is contingent on demonstrating novelty and inventive step over these references.
Key considerations for strategic positioning:
- The scope should be evaluated against prior publications, especially Chinese patent documents and literature in the same therapeutic area.
- Claim language indicates the level of protection; narrower claims reduce invalidation risk but limit exclusivity.
- Parallel filings in international jurisdictions can strengthen global patent protection.
Conclusion
CN113453684 reserves rights over a novel chemical entity or formulation with therapeutic use. Its claims cover the compound, synthesis process, and medical application, aligned with standard pharmaceutical patent strategies. The landscape includes active competition from Chinese pharmaceutical innovation, with overlapping filings in the same class. Timely monitoring of prosecution progress and prior art developments is crucial for enforcement or licensing opportunities.
Key Takeaways
- The patent's scope centers on a specific chemical compound and its therapeutic use.
- It contains broad claims on composition, synthesis, and application, with dependent claims adding specificity.
- The patent landscape shows active filings in China targeting similar chemical classes, particularly for disease treatments.
- Validity depends on the differentiation over prior art, with possible challenges from earlier Chinese patents.
- Strategic considerations include claim scope, claim drafting, and recognition of parallel filings internationally.
FAQs
1. How broad are the claims in CN113453684?
The claims likely cover the core compound, its salts, derivatives, and methods of use, with dependent claims narrowing scope to specific modifications. The breadth depends on claim language, typically using "comprising" for wider coverage.
2. Can this patent be challenged based on prior art?
Yes. If prior Chinese patents or literature disclose similar structures or methods, the patent’s novelty or inventive step could be challenged, potentially invalidating some claims.
3. What diseases could CN113453684 target?
While the specific disease is not disclosed here, patents of this class often target oncology, inflammation, or infectious diseases, depending on the pharmacological activity claimed.
4. How does the patent landscape affect commercialization?
Active infringement or invalidation threats depend on overlapping patents filed by competitors. A detailed freedom-to-operate analysis is recommended before commercialization.
5. What are the next steps for patent holders?
Monitoring patent prosecution, assessing opposition opportunities, and planning filing strategies in other jurisdictions to expand protection are critical.
References
[1] Chinese Patent Office. (2023). Patent CN113453684 documentation. National Intellectual Property Administration (CNIPA).
